Entrada Therapeutics (TRDA) Financial Statements & Analysis

Entrada Therapeutics (TRDA) Income Statement

Entrada Therapeutics reported revenue of $25.42M in fiscal 2025 (fiscal year ended Dec 31, 2025), down 87.9% from $210.78M a year earlier. Entrada Therapeutics posted a net loss of $143.75M, compared with net income of $65.63M a year earlier. Gross margin was 100.0% and operating margin -621.1%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $898.00K, down 53.9% from the same quarter a year earlier.

Entrada Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Entrada Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Revenue & Gross Profit
Revenue	25.42	210.78	129.01	0.00	0.00	0.00	0.00
Cost of Revenue	140.57	0.00	0.00	0.00	35.93	0.33	0.10
Gross Profit	25.42	210.78	129.01	0.00	-35.93	-0.33	-0.10
Operating Expenses
Research & Development	142.27	125.31	99.88	66.61	35.93	21.10	8.22
Selling, General & Administrative	40.85	38.47	32.29	30.64	15.20	5.57	3.61
Operating Expenses	183.32	163.77	132.18	97.25	51.13	26.67	11.82
Operating Income	-157.90	47.01	-3.16	-97.25	-51.13	-26.67	-11.82
Other Income/Expense
Interest Income	15.07	19.47	15.22	2.63	-0.03	0.16	0.00
Interest Expense	0.00	0.00	0.00	2.63	0.00	0.00	0.00
Other Income/Expense	15.07	19.47	15.22	2.63	-0.03	0.14	6.72
Income
Income Before Tax	-142.83	66.49	12.06	-94.62	-51.16	-26.52	-5.10
Income Tax Expense	0.92	0.86	18.74	0.00	0.00	0.00	0.00
Net Income	-143.75	65.63	-6.69	-94.62	-51.16	-26.52	-4.65
Net Income - Continuous Operations	-143.75	65.63	-6.69	-94.62	-51.16	-26.52	-4.65
Net Income - Discontinued Operations	-	-	-	-	-	-	-
EBITDA	-151.90	70.26	14.90	-90.09	-50.01	-26.34	-11.72
EBIT	-156.00	47.01	-3.16	-97.25	-51.13	-26.67	-
Depreciation & Amortization	4.10	3.77	2.84	1.90	1.12	0.33	0.10
Earnings Per Share
Basic EPS	-3.00	2.00	-	-3.00	-8.00	-24.00	-4.00
Diluted EPS	-3.00	2.00	-	-3.00	-8.00	-24.00	-4.00
Basic Shares Outstanding	41.37	37.31	33.05	31.29	6.27	1.11	1.05
Diluted Shares Outstanding	41.37	39.00	33.05	31.29	6.27	1.11	1.05

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Entrada Therapeutics Financial Statements

What was Entrada Therapeutics's revenue in fiscal 2025?

Entrada Therapeutics reported revenue of $25.42M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 87.9% from $210.78M a year earlier.

Is Entrada Therapeutics profitable?

No. Entrada Therapeutics reported a net loss of $143.75M in fiscal 2025. In fiscal 2024 it earned $65.63M.

What is Entrada Therapeutics's operating margin?

Entrada Therapeutics's operating income was −$157.90M on revenue of $25.42M in fiscal 2025, an operating margin of -621.1%, compared with 22.3% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition